Monday, March 09, 2015 6:06:19 AM
Are There Any Small-Cap Gems In Health Care? ( http://www.benzinga.com/general/biotech/15/03/5303907/are-there-any-small-cap-gems-in-health-care )
David Miller Catalyst Funds ( http://www.catalystmutualfunds.com/ )
March 05, 2015 11:02pm
David Miller is Senior Portfolio Manager of the Catalyst Insider Buying Fund and the Catalyst Small-Cap Insider Buying Fund, the latter of which was named the top equities mutual fund of the year by the Wall Street Journal in 2014.
Today's market conditions are plagued with several "what ifs" that have made it difficult, if not near impossible, to identify strong investments. Between the looming rise of interest rates, worries over Greece and the rising dollar, the equities market is in constant flux.
In these times of uncertainty, there are some stocks that continue to present a unique investment opportunity with the potential for very strong upside, such as small-cap health care stocks.
Traditional investment assessment of these stocks can be challenging, simply because the development process is long and requires acute technical knowledge. However, there are some signals, which even the least technical investor can look to as good indicators to buy or sell shares in companies.
Looking to the people running the company – the "insiders" – can help navigate these stocks and identify companies that are a good investment. If top executives and directors, who know their company better than anyone else, start buying in an unusual manner, there may be some positive developments on the horizon, including a successful clinical trial update, strategic partnership or potential M&A talk.
We continue to see insider activity within the small-cap health care space that suggests this market sector is primed for growth.
Catalyst Pharmaceutical and Opko Health are two recent examples of companies with significant insider buying, alluding to a strong future growth trajectory:
Opko Health Inc.
Opko Health has experienced substantial upside over the past three months, following significant insider buying in 2014. The stock is up 74 percent compared to just a 2 percent return for the S&P 500 Total Return Index.
Despite this impressive rally, CEO Phillip Frost, M.D. continues to buy stock, a telling signal of the potential upside still left in Opko.
Frost bought $3.2 million of Opko in January at an average price of $10.18 and an additional $644,000 in February at an average price of $12.89. The stock was trading in the $14 range by the end of February. He continued to purchase another $626,000 of Opko after the rally on March 2 at a price of $13.98.
Frost's open market purchases suggest the company is on a track for strong growth.
Opko reported earnings on February 27 with total revenue increasing 23 percent year-over-year. The EPS of ($0.07) was in line with Street consensus. Year to date, Opko has rallied from $10 to $14.
There are several catalysts fueling Opko's potential growth.
The company has a Rayaldee NDA filing scheduled for the first quarter of 2015. Opko's 4Kscore test is ramping up nicely, with over 550 urologists using 4Kscore in their practice. The 4Kscore test has the potential for additional uptake and increased reimbursement coverage over the longer term.
Finally, Opko announced it partnered with Pfizer, who licensed the rights to Opko's long-acting human growth hormone, hGH-CTP.
The top analyst covering Opko according to the Bloomberg Absolute Return Rank, Kevin DeGeeter of Ladenburg Thalmann & Co., raised his price target to $18.50, showing that Wall Street also sees potential upside to the Opko story.
Catalyst Pharmaceutical Partners, Inc.
Catalyst Pharmaceutical operates as a development-stage specialty pharmaceutical company focusing on rare (orphan) diseases and disorders. Its principal product candidate is Firdapse, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome.
From May 2014 through January 2015, Catalyst corporate insiders took a large position in the stock. During this time insiders, including CEO Patrick McEnany and Chief Operating Officer Steve Miller, purchased over 225,000 shares of Catalyst with no insiders selling.
Catalyst has the potential to more than double in price with a successful U.S. launch of its primary drug Firdapse. Firdapse was launched in the European Union in April 2010, and post-marketing clinical data has been collected since then.
This data will likely increase the probability of FDA approval. With orphan drug status, Firdapse is entitled to seven-year market exclusivity period after FDA approval.
Catalyst believes the North America market potential could be $100 million annually, with potential upside driven by more favorable pricing in the U.S. than in the EU and possible label expansion.
Catalyst has already increased from around $1.80 a share in May 2014 to $3.76 a share as of February 28, 2015. If news of a successful Phase III clinical trial breaks, this price is likely to surge even more.
Recent OPK News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:29:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:07:44 PM
- OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 05/03/2024 12:00:00 PM
- Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business • PR Newswire (US) • 03/28/2024 12:00:00 PM
- Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 09:02:37 PM
- AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV • GlobeNewswire Inc. • 03/05/2024 01:52:22 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 09:05:23 PM
- NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st • PR Newswire (US) • 02/28/2024 02:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:07:54 PM
- OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024 • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/16/2024 09:53:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:07:24 PM
- NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China • PR Newswire (US) • 02/05/2024 01:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 08:30:14 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:00:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:09:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:56:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:09:07 PM
- OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes • GlobeNewswire Inc. • 01/09/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 02:10:34 PM
- OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM